Article
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Asia-Pacific journal of clinical oncology - 1 Mar 2011
Metharom Ekkaphon, Galettis Peter, Manners Susan, Jelinek Maria, Liauw Winston, de Souza Paul L, Hoskins Janelle M, Links Matthew
Abstract excerpt
AIM: Controversy exists over the optimal dosing for the nucleoside analogue gemcitabine. A pharmacological advantage is achieved by prolonging infusion times but evidence for a clinical benefit has been conflicting. We hypothesized that polymorphisms in genes involved in gemcitabine accumulation, particularly the cytidine deaminase CDA c.79A>C, may influence the optimal dosing regimen in individual patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.